Streetbeat News

Equity Actions

FWBI

First Wave BioPharma, Inc. (NASDAQ:FWBI) announced a registered direct offering of 525,625 shares at $7.61 per share, aiming to raise approximately $4M. Additionally, the company will issue warrants for the same number of shares at $7.48 per share in a private placement. Roth Capital Partners is the placement agent. The proceeds will be used for working capital and general corporate purposes, with the offering's closing expected around March 6, 2024.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 1:03 pm

RXRX

Four analysts have recently updated their ratings on Recursion Pharmaceuticals (NASDAQ:RXRX), showing a shift towards a more bullish outlook over the last three months. The average 12-month price target for RXRX has been raised to $15.75, reflecting a 5.0% increase from the previous target of $15.00. Analysts from Keybanc and Needham have adjusted their price targets and ratings, indicating a positive sentiment towards the company's market performance. Despite this, Recursion Pharmaceuticals faces challenges in profitability and debt management, with a net margin of -875.34% and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 1:02 pm

PGR

Progressive (NYSE:PGR) has received mixed analyst ratings over the last quarter, with a total of 9 analysts offering varied perspectives. The recent updates show a shift towards more bullish sentiments, with price targets being raised by several analysts, indicating a positive outlook on the stock. The average 12-month price target is now $191.89, up from $182.14, suggesting a 5.35% increase. Progressive's financial performance shows strong revenue growth and ROE, but challenges in net margin and debt management.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 1:02 pm

MTDR

Matador Resources (NYSE:MTDR) has received mixed analyst ratings over the past quarter, with recent evaluations adjusting price targets and ratings. The average 12-month price target is now $68.4, down from $74.00, reflecting a 7.57% decline. Analysts from firms like TD Cowen, Benchmark, Keybanc, Raymond James, and Mizuho have made adjustments based on the company's performance and market conditions. Matador Resources, an independent energy company, has shown solid revenue growth and exceptional net margin but faces challenges with ROE, ROA, and high debt levels.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 1:01 pm

AI

C3.ai (NYSE:AI) received mixed analyst ratings with a trend towards neutral positions. Six analysts provided ratings, with five being indifferent and one somewhat bearish. The average 12-month price target is $27.67, showing a 6.42% increase from the previous $26.00. Analysts from firms like Piper Sandler and B of A Securities adjusted their price targets, reflecting a nuanced view of C3.ai's market performance. Despite a positive revenue trend, C3.ai's financial indicators such as net margin and ROE lag behind industry averages, suggesting challenges ahead.

Portfolio Pulse from Benzinga Insights

March 04, 2024 | 1:00 pm

NFE

New Fortress Energy (NFE) has announced its intention to offer $500 million of senior secured notes. This move is aimed at raising capital, possibly for expansion, debt refinancing, or other corporate purposes. The offering's specifics, such as the interest rate, maturity date, and use of proceeds, were not disclosed in the announcement.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:42 pm

SMCI

Super Micro Computer (SMCI) shares are trading higher after the announcement that it will join the S&P 500. Additionally, Goldman Sachs initiated coverage on SMCI with a Neutral rating and set a price target of $941.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:42 pm

BLKB

Blackbaud (NASDAQ:BLKB) announced plans to repurchase 7%-10% of its outstanding shares by the end of 2024, utilizing a mix of accelerated share repurchase plans, block trades, and open market purchases. This move is part of its previously announced $500 million share repurchase authorization.

Portfolio Pulse from Benzinga Newsdesk

March 04, 2024 | 12:35 pm

XRTX

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, has announced the completion of a second tranche closing, raising CAD $224,850 through a prospectus supplement and a concurrent private placement. This funding is part of a previously announced offering aimed at developing therapies for progressive kidney disease. The private placement included international subscribers, contributing CAD $99,000 to the total raised funds.

Portfolio Pulse from Charles Gross

March 04, 2024 | 12:21 pm

TELL

Tellurian Inc. announced that its board has decided not to renew or extend CEO Octávio Simões' employment agreement beyond June 5, 2024. Additionally, Martin Houston has been named as the Executive Chairman effective February 27.

Portfolio Pulse from Charles Gross

March 04, 2024 | 12:19 pm